Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 02, 2015 16:16 ET | Source: Galapagos NV

Galapagos raises EU1.2 million through warrant exercises

MECHELEN, Belgium, Oct. 2, 2015 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext & NASDAQ: GLPG) announced a share capital increase arising from warrant exercises. As a result of warrant exercises,...
October 02, 2015 16:01 ET | Source: Galapagos NV

Galapagos haalt €1,2 miljoen op door uitoefening van warrants

Mechelen, België; 2 oktober 2015 - Galapagos NV (Euronext & NASDAQ: GLPG) kondigt een kapitaalverhoging aan als gevolg van de uitoefening van warrants. Aansluitend op de...
October 02, 2015 16:01 ET | Source: Galapagos NV

Galapagos raises €1.2 million through warrant exercises

Mechelen, Belgium; 2 October 2015 - Galapagos NV (Euronext & NASDAQ: GLPG) announced a share capital increase arising from warrant exercises. As a result of warrant exercises, Galapagos...
September 25, 2015 10:44 ET | Source: Galapagos NV

Galapagos to advance filgotinib to Phase 3 in rheumatoid arthritis

Galapagos regains all unencumbered rights to filgotinib Filgotinib is the most selective JAK1 inhibitor Best-in-class efficacy and safety in RA in 24-week Phase 2B studies in 877 patientsPhase 3...
September 25, 2015 10:44 ET | Source: Galapagos NV

Galapagos to advance filgotinib to Phase 3 in rheumatoid arthritis

Galapagos regains all unencumbered rights to filgotinib Filgotinib is the most selective JAK1 inhibitor Best-in-class efficacy and safety in RA in 24-week Phase 2B studies in 877 patientsPhase 3...
September 22, 2015 01:30 ET | Source: Galapagos NV

Galapagos presenteert positieve Fase 1 resultaten met GLPG1690 op ERS congres

Mechelen, Belgium; 22 september 2015: Galapagos NV (Euronext & NASDAQ: GLPG) presenteert preklinische en Fase 1 resultaten voor autotaxin remmer GLPG1690 op het jaarlijkse longziekten congres...
September 22, 2015 01:30 ET | Source: Galapagos NV

Galapagos presents promising pre-clinical and Phase 1 results with autotaxin inhibitor GLPG1690 at ERS

Mechelen, Belgium; 22 September 2015: Galapagos NV (Euronext & NASDAQ: GLPG) presents pre-clinical and Phase 1 results for autotaxin inhibitor GLPG1690 at the European Respiratory Society...
August 10, 2015 16:00 ET | Source: Galapagos NV

DARWIN 2 24-weken monotherapie gegevens in reuma bevestigen eerdere resultaten en ondersteunen het best-in-class potentieel van filgotinib

ACR50 scores tot 45% met eenmaal daagse monotherapie Tot 50% van de patiënten bereikt een DAS28(CRP) status van weinig of geen symptomen 100 mg en 200 mg dagelijkse dosering vertonen...
August 10, 2015 16:00 ET | Source: Galapagos NV

DARWIN 2 24-week monotherapy data in RA confirm previous results and support best-in-class potential for filgotinib

ACR50 responses up to 45% as once-daily monotherapy DAS28(CRP) low disease activity up to 50% Similar efficacy at 100 and 200 mg Safety profile in DARWIN 2 consistent with previous...
August 06, 2015 01:30 ET | Source: Galapagos NV

Galapagos rondt werving van patiënten af in FITZROY Fase 2 studie met filgotinib in de ziekte van Crohn

Eerste JAK1-remmer wereldwijd in Fase 2 studie voor ziekte van Crohn 175 patiënten nemen deel aan 20-weken behandeling Eerste, primaire eindpunt resultaten verwacht in december 2015 ...